NasdaqGS:REGNBiotechs
Regeneron Pharmaceuticals (REGN) Could Be 19% Undervalued After Recent Pipeline Focus
Event overview and why Regeneron Pharmaceuticals stock is in focus
Regeneron Pharmaceuticals (REGN) is back in the spotlight after a new collaboration with Telix Pharmaceuticals to co develop radiopharmaceutical cancer therapies, alongside securities class action filings tied to disclosures around its Fianlimab Libtayo Phase III study.
See our latest analysis for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals' share price has climbed 10.7% over the past month but is still down 13.0%...